While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...

Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

The global market for Biological Drugs was estimated at US$345.3 Billion in 2023 and is projected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive ...

By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Mumbai: Global pharma major Lupin Limited and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug ...

Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare ...

Seed Therapeutics Inc.’s ST-01156 has been awarded orphan drug designation for the treatment of Ewing sarcoma as well as rare pediatric disease designation by the FDA.

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...